Imagine a dangerous virus spread by ticks that causes severe bleeding. This work creates a high-tech 'instruction manual' (mRNA) to teach the body to fight it and develops custom-made antibodies that act like precision missiles to neutralize the virus. It's like building a double-layered security system for the body to prevent and treat a deadly infection.
There is a critical lack of effective vaccines and treatments for Crimean-Congo Haemorrhagic Fever, a severe zoonotic threat exacerbated by climate change.
An mRNA vaccine candidate, a pipeline for monoclonal antibodies from patient B cells, and a biobank of CCHF patient samples.
If you are a vaccine manufacturer dealing with the rise of tick-borne diseases due to climate change — this project developed mRNA vaccine candidates and a production roadmap that accelerates the path to Phase I clinical trials.
If you are a biotech firm dealing with a lack of therapeutic options for viral hemorrhagic fevers — this project developed a pipeline to produce monoclonal antibodies (mAbs) from patient B cells that can be used as immunotherapy.
If you are a health infrastructure provider dealing with fragmented sample data — this project developed a biobank from CCHF patients and harmonized pipelines for clinical sample collection and analysis.
Based on available project data, there is no information regarding the cost or pricing of the vaccine candidates.
The project focuses on establishing a platform for mRNA-based vaccines and a roadmap for Phase I trials, but industrial scale-up data is not provided.
Based on available project data, specific IP or licensing terms are not mentioned.
The project aims to develop a road map to bring the most efficacious candidates to clinical trial Phase I in humans by the end of the period in 2027.
Results will be shared with public health authorities, outbreak management teams, and hospitals to increase preparedness for new outbreaks.
The consortium is heavily weighted toward research and academia, consisting of 15 partners across 10 countries. With 9 research organizations and 4 universities, and 0% industry participation, the project is currently in a high-science phase focused on discovery and pre-clinical validation rather than immediate commercialization.
Contact FOLKHALSOMYNDIGHETEN in Sweden
Contact us to identify potential licensing opportunities as the project moves toward Phase I trials.
